Benjamin Qu

WORK HISTORY

EDUCATION

ABOUT BENJAMIN QU

I am a dedicated Scientific Business Development Manager at Cyagen Biosciences B.V, based in Germany. I am more than confident since I have a triple role as a new-generation BD manager: communicating efficiently with you as a salesman; presenting our models and CRO services as a lecturer, and designing new projects with you as a scientist.Tell me your requests, we will take care of the rest. What I experienced in my Ph.D, 4-year postdoc and 2-year PI research career definitely empowers me as a reliable collaborator.The following paragraphs are not important, but I truly appreciate if you read to the end- Motivated researcher with twelve years of experience in virology, immunology and hepatology- Extensive hands-on experience in biochemistry and molecular biology- Highly experienced in developing a broad range of bioassays (cell-based assays, immunoassays, protein- and nucleic acid-based approaches)- Supervision of graduates, undergraduates and exchange students (DAAD RISE-Germany Program), technicians and interns- Success in collaborative, multidisciplinary teams with robust multi-task, problem-solving and communication skills- 320 working entries in biosafety level 3 (BSL3) facility for highly pathogenic influenza and SARS/MERS/SARS-CoV-2 research projects- Qualified to perform mouse, hamster and zebrafish experiments (FELASA-B, EU)- R programming beginner with a great interest- Oral presentations in 8 international conferences and poster presentations in 10 conferences- Published 36 peer-reviewed articles and 1 patent (WO20••••••91A4)- Previous) Editorial board members of \"Journal of Clinical Virology\",\"Antimicrobial Agents and Chemotherapy\" and \"Vaccines (Basel)\"- Guest Editors of \"Vaccines\" and \"Viruses\"- Reviewer 72 manuscripts for 19 journals- Grant reviewer for the Fondation pour la Recherche Médicale- Membership of the German Society for Virology (GfV), European Society for Virology (ESV) and European Virus Bioinformatics Center (EVBC)- Participated in BMBF Virascreen funding (2023~2024); BMG Charis Coronavirus funding (2020~2022); DFG SFB/TRR179 funding (2016~2020)(Grant number 27•••••13); DFG funding (2013~2016)(Grant number 13•••••50); National Natural Science Foundation of China funding (2010~2012)(Grant number 30••••50).